Open Orphan has announced a new challenge study contract win which follows from the announcement yesterday regarding a contract renewal with a large global pharmaceutical customer for the Venn business. This pipeline conversion builds on existing relationships and supports the Group's target to drive high value recurring revenue using the embedded IP within hVivo and Venn
17 Nov 2021
Open Orphan* - New RSV Challenge Study Contract
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Open Orphan* - New RSV Challenge Study Contract
hVIVO plc (HVO:LON) | 29.0 0 0.0% | Mkt Cap: 197.3m
- Published:
17 Nov 2021 -
Author:
Andrew Simms | Philip Modu -
Pages:
5
Open Orphan has announced a new challenge study contract win which follows from the announcement yesterday regarding a contract renewal with a large global pharmaceutical customer for the Venn business. This pipeline conversion builds on existing relationships and supports the Group's target to drive high value recurring revenue using the embedded IP within hVivo and Venn